Cited by 89Cholesterol and Lipid MetabolismLipoproteins and Cardiovascular HealthLipid metabolism and disorders

Molecular Basis for the Differences in Lipid and Lipoprotein Binding Properties of Human Apolipoproteins E3 and E4

Open access
Nguyen, David, Dhanasekaran, Padmaja, Nickel, Margaret, Nakatani, Ryosuke, Saito, Hiroyuki, Phillips, Michael C., Lund-Katz, Sissel·2010·Biochemistry

Abstract

Human apolipoprotein (apo) E4 binds preferentially to very low-density lipoproteins (VLDLs), whereas apoE3 binds preferentially to high-density lipoproteins (HDLs), resulting in different plasma cholesterol levels for the two isoforms. To understand the molecular basis for this effect, we engineered the isolated apoE N-terminal domain (residues 1-191) and C-terminal domain (residues 192-299) together with a series of variants containing deletions in the C-terminal domain and assessed their lipid and lipoprotein binding properties. Both isoforms can bind to a phospholipid (PL)-stabilized triolein emulsion, and residues 261-299 are primarily responsible for this activity. ApoE4 exhibits better lipid binding ability than apoE3 as a consequence of a rearrangement involving the segment spanning residues 261-272 in the C-terminal domain. The strong lipid binding ability of apoE4 coupled with the VLDL particle surface being ∼60% PL-covered is the basis for its preference for binding VLDL rather than HDL. ApoE4 binds much more strongly than apoE3 to VLDL but less strongly than apoE3 to HDL(3), consistent with apoE-lipid interactions being relatively unimportant for binding to HDL. The preference of apoE3 for binding to HDL(3) arises because binding is mediated primarily by interaction of the N-terminal helix bundle domain with the resident apolipoproteins that cover ∼80% of the HDL(3) particle surface. Thus, the selectivity in the binding of apoE3 and apoE4 to HDL(3) and VLDL is dependent upon two factors: (1) the stronger lipid binding ability of apoE4 relative to that of apoE3 and (2) the differences in the nature of the surfaces of VLDL and HDL(3) particles, with the former being largely covered with PL and the latter with protein.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/bi1017655

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • APOE3 has a higher affinity for HDL, whereas APOE4 is more likely to bind LDL and VLDL.

    “APOE3 has a higher affinity for HDL, whereas APOE4 is more likely to bind LDL and VLDL102.”

    From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [102]

    The Discussion (Lipoprotein Interactions of ApoE3 and ApoE4; page unavailable) says apoE3 binds better than apoE4 to HDL3, while apoE4 binds better than apoE3 to VLDL. The study compares HDL3 and VLDL, but the passages do not establish a preference for LDL; the LDL part of the claim is unsupported. (LLM, conf=0.89)

    Experimental — accuracy not yet measured
  • ApoE3 and ApoE4 have normal binding ability to LDLR, while ApoE2 exhibits a binding defect with LDLR, leading to impaired lipid clearance and its association with type III hyperlipoproteinemia.

    “ApoE3 and ApoE4 have normal binding ability to LDLR, while ApoE2 exhibits a binding defect with LDLR, leading to impaired lipid clearance and its association with type III hyperlipoproteinemia.[14]”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 27

  1. [2]Getz GS Reardon CA 2009 Apoprotein E as a lipid transport and signaling protein in the blood, liver, and artery wall J Lipid Res 50 S156 S161 19018038 PMC2674757
  2. [3]Curtiss LK Boisvert WA 2000 Apolipoprotein E and atherosclerosis Curr Opin Lipidol 11 243 251 10882339
  3. [5]Mahley RW Huang Y Rall SC 1999 Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes J Lipid Res 40 1933 1949 10552997
  4. [7]Lahoz C Schaefer EJ Cupples LA Wilson PW Levy D Osgood D Parpos S Pedro-Botet J Daly JA Ordovas JM 2001 Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study Atherosclerosis 154 529 537 11257253
  5. [8]Weisgraber KH Innerarity TL Mahley RW 1982 Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site J Biol Chem 257 2518 2521 6277903
  6. [9]Steinmetz A Jakobs C Motzny S Kaffarnik H 1989 Differential distribution of apolipoprotein E isoforms in human plasma lipoproteins Arteriosclerosis 9 405 411 2719600
  7. [11]Morrow JA Segall ML Lund-Katz S Phillips MC Knapp M Rupp B Weisgraber KH 2000 Differences in stability among the human apolipoprotein E isoforms determined by the amino-terminal domain Biochemistry 39 11657 11666 10995233
  8. [13]Dong LM Wilson C Wardell MR Simmons T Mahley RW Weisgraber KH Agard DA 1994 Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms J Biol Chem 269 22358 22365 8071364
  9. [14]Dong LM Weisgraber KH 1996 Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins J Biol Chem 271 19053 19057 8702576
  10. [15]Drury J Narayanaswami V 2005 Examination of lipid-bound conformation of apolipoprotein E4 by pyrene excimer fluorescence J Biol Chem 280 14605 14610 15708851
  11. [16]Hatters DM Budamagunta MS Voss JC Weisgraber KH 2005 Modulation of apolipoprotein E structure by domain interaction. Differences in lipid-bound and lipid-free forms J Biol Chem 280 34288 34295 16076841
  12. [17]Sakamoto T Tanaka M Vedhachalam C Nickel M Nguyen D Dhanasekaran P Phillips MC Lund-Katz S Saito H 2008 Contributions of the carboxyl-terminal helical segment to the self-association and lipoprotein preferences of human apolipoprotein E3 and E4 isoforms Biochemistry 47 2968 2977 18201068 PMC2692928
  13. [18]Saito H Dhanasekaran P Baldwin F Weisgraber KH Phillips MC Lund-Katz S 2003 Effects of polymorphism on the lipid interaction of human apolipoprotein E J Biol Chem 278 40723 40729 12917433
  14. [20]Tanaka M Vedhachalam C Sakamoto T Dhanasekaran P Phillips MC Lund-Katz S Saito H 2006 Effect of carboxyl-terminal truncation on structure and lipid interaction of human apolipoprotein E4 Biochemistry 45 4240 4247 16566598
  15. [21]Chroni A Pyrpassopoulos S Thanassoulas A Nounesis G Zannis VI Stratikos E 2008 Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: Insights into secondary structure and unfolding properties Biochemistry 47 9071 9080 18690708 PMC2692411
  16. [22]Morrow JA Arnold KS Weisgraber KH 1999 Functional characterization of apolipoprotein E isoforms overexpressed in escherichia coli Protein Expr Purif 16 224 230 10419818
  17. [25]Lowry OH Rosebrough NJ Farr AL Randall RJ 1951 Protein measurement with the folin phenol reagent J Biol Chem 193 265 275 14907713
  18. [26]Nguyen D Dhanasekaran P Phillips MC Lund-Katz S 2009 Molecular mechanism of apolipoprotein E binding to lipoprotein particles Biochemistry 48 3025 3032 19209940 PMC2765560
  19. [27]Segall ML Dhanasekaran P Baldwin F Anantharamaiah GM Weisgraber K Phillips MC Lund-Katz S 2002 Influence of apoE domain structure and polymorphism on the kinetics of phospholipid vesicle solubilization J Lipid Res 43 1688 1700 12364553
  20. [28]Saito H Dhanasekaran P Nguyen D Holvoet P Lund-Katz S Phillips MC 2003 Domain structure and lipid interaction in human apolipoproteins A-I and E: A general model J Biol Chem 278 23227 23232 12709430
  21. [30]Sivashanmugam A Wang J 2009 A unified scheme for initiation and conformational adaptation of human apolipoprotein E N-terminal domain upon lipoprotein-binding and for receptor-binding activity J Biol Chem 284 14657 14666 19307174 PMC2682913
  22. [31]Saito H Lund-Katz S Phillips MC 2004 Contributions of domain structure and lipid interaction to the functionality of exchangeable human apolipoproteins Prog Lipid Res 43 350 380 15234552
  23. [32]Shen BW Scanu AM Kezdy FJ 1977 Structure of human serum lipoproteins inferred from compositional analysis Proc Natl Acad Sci USA 74 837 841 265578 PMC430495
  24. [33]Ibdah JA Lund-Katz S Phillips MC 1989 Molecular packing of high-density and low-density lipoprotein surface lipids and apolipoprotein A-I binding Biochemistry 28 1126 1133 2496753
  25. [34]Phillips MC Krebs KE 1986 Studies of apolipoproteins at the air-water interface Methods Enzymol 128 387 403 3724515
  26. [35]Narayanaswami V Ryan RO 2000 Molecular basis of exchangeable apolipoprotein function Biochim Biophys Acta 1483 15 36 10601693
  27. [36]Lund-Katz S Nguyen D Dhanasekaran P Kono M Nickel M Saito H Phillips MC 2010 Surface plasmon resonance analysis of the mechanism of binding of apoA-I to high density lipoprotein particles J Lipid Res 51 606 617 19786567 PMC2817590

Cited by

Sorted by citations

Authors
Nguyen, D., Dhanasekaran, P., Nickel, M., Nakatani, R., Saito, H., Phillips, M. C., & Lund-Katz, S.
Affiliations
  • Children's Hospital of Philadelphia (US)
  • Tokushima University (JP)
  • Lipid Research Group, Division of Gastroenterology, Hepatology and Nutrition, The Children’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-4318, United States
Venue
Biochemistry
Published
2010-12-03
Volume
49
Issue
51
Pages
10881-10889
ISSN
  • 0006-2960 (ISSN-L)
  • 1520-4995
OpenAlex
W2325931377
Cited by
89
References
9
Citations by year
2026: 7 · 2025: 11 · 2024: 10 · 2023: 9 · 2022: 1 · 2021: 9 · 2020: 3 · 2019: 8 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 3 · 2014: 6 · 2013: 3 · 2012: 4
FWCI
3.38
Type
journal article
Language
en
Open access
Locations
  • Biochemistry (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Japan Society for the Promotion of Science (22590046)
  • National Heart, Lung, and Blood Institute (R01HL056083, HL-56083)
Topics
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
Keywords
apolipoprotein E, apolipoprotein E3, APOE ε4, isoform selectivity, lipid binding, lipoprotein binding, VLDL, HDL3, C-terminal domain, serum cholesterol
MeSH terms
Escherichia coli, Humans, Lipoproteins, Lipoproteins, HDL, Lipoproteins, VLDL, Mutation, Protein Binding, Gene Expression, Protein Structure, Tertiary, Protein Isoforms, Lipid Metabolism, Apolipoprotein E3, Apolipoprotein E4

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review